{
  "patient_profile": "Patient with Non-Small Cell Lung Cancer, Adenocarcinoma. Disease occurred in lung. Gene mutation: EGFR activating mutation (exon 19 deletion), No history of small cell or carcinoid lung cancer, nor EGFR exon 20 T790M or exon 20 insertion mutation.. ECOG score is 0. Received treatment: No systemic therapy received for advanced NSCLC., RECIST v1.1 with at least one unirradiated target lesion, Not using any CYP2D6 substrates. Biomarkers are Platelets: 110,000 cells/mm, Creatinine: 35 mL/min, ALT (SGPT): Within normal limits, AST (SGOT): Within normal limits, Bilirubin, Total: 1.2 x ULN, ECOG: 0, ANC: 1600 cells/mm, Hemoglobin: 11.0 g/dL, Bilirubin: 1.2 x ULN. Other health status: Smoking status unknown.",
  "ranked_sql_trials": [
    "NCT04027647",
    "NCT05261399",
    "NCT04989322",
    "NCT05526755",
    "NCT05133544",
    "NCT05170204",
    "NCT04782557",
    "NCT05425940",
    "NCT05099172",
    "NCT05048797"
  ],
  "evaluate_trials": [
    {
      "trial_id": "NCT04027647",
      "gpt_result_score": 13,
      "embedding_score": 5,
      "criteria": [
        {
          "id": 0,
          "type": "exclusion",
          "criterion": "Any evidence of mixed histo- and/or cytology that includes elements of small cell or carcinoid lung cancer. Variations of adenocarcinoma are allowed, however no squamous element can be present;",
          "match_result": "neutral",
          "comment": "The patient's profile mentions Non-Small Cell Lung Cancer, Adenocarcinoma, with no history of small cell or carcinoid lung cancer, which aligns with the criterion. However, more information is needed regarding the presence of squamous elements to definitively determine if the criterion is met."
        },
        {
          "id": 1,
          "type": "exclusion",
          "criterion": "An EGFR exon 20 T790M or exon 20 insertion mutation;",
          "match_result": "negative",
          "comment": "The patient's gene mutation is specifically mentioned as No EGFR exon 20 T790M or exon 20 insertion mutation, which indicates that the patient does not have the mutation mentioned in the criterion. Therefore, the patient does not meet the criterion for exclusion based on the EGFR mutation status."
        },
        {
          "id": 2,
          "type": "exclusion",
          "criterion": "Symptomatic brain or leptomeningeal metastases, who are neurologically unstable or require increasing doses of steroids and/or anti-seizure medications to manage CNS symptoms within two weeks prior to starting dacomitinib;",
          "match_result": "negative",
          "comment": "The patient has a history of brain metastases, making them not eligible for the clinical trial criteria as they should not have symptomatic brain or leptomeningeal metastases within two weeks prior to starting dacomitinib."
        },
        {
          "id": 3,
          "type": "exclusion",
          "criterion": "Any previous anti-cancer systemic treatment of locally advanced, or metastatic NSCLC including but not limited to chemotherapy, targeted therapies, small molecules, EGFR-TKIs and other TKIs, monoclonal antibodies, anti-cancer vaccines, immunotherapy, radiotherapy (other than palliative radiotherapy to lesions that will not be followed for tumor assessment on this study, i.e., non-target lesions). Completed neoadjuvant/adjuvant chemotherapy/immunotherapy and/or combined modality chemotherapy/ radiation therapy permitted only in cases in which there is a minimum of 12 months disease free interval between completion of systemic therapy and recurrence of NSCLC. Prior treatment with a EGFR-TKI or other TKIs is not allowed;",
          "match_result": "negative",
          "comment": "The patient has a history of EGFR activating mutation and has not received any systemic therapy for advanced NSCLC, which aligns with the criterion. However, the patient's disease-free interval between completion of systemic therapy and recurrence of NSCLC is not mentioned, and since there is no evidence of a minimum 12 months disease-free interval, the criterion is not fully met. Additionally, the patient's EGFR-TKI treatment history contradicts the criterion, as prior treatment with EGFR-TKI is not allowed."
        },
        {
          "id": 4,
          "type": "exclusion",
          "criterion": "Any surgery (not including minor procedures such as lymph node biopsy), palliative radiotherapy or pleurodesis within 2 weeks of baseline assessments;",
          "match_result": "negative",
          "comment": "The patient has not undergone any surgery, palliative radiotherapy, or pleurodesis within 2 weeks of baseline assessments. Therefore, the criterion is present in the patient profile, but it does not meet the exclusion criteria as required by the clinical trial."
        },
        {
          "id": 5,
          "type": "exclusion",
          "criterion": "Any clinically significant gastrointestinal abnormalities that may impair intake, transit or absorption of the study drug, such as the inability to take oral medication;",
          "match_result": "negative",
          "comment": "The patient has no reported gastrointestinal abnormalities that may impair intake, transit, or absorption of the study drug. Therefore, the patient does not meet the criterion of having clinically significant gastrointestinal abnormalities as specified in the clinical trial criteria."
        },
        {
          "id": 6,
          "type": "exclusion",
          "criterion": "Current enrollment in another therapeutic clinical study;",
          "match_result": "negative",
          "comment": "The patient does not meet the criterion as there is no evidence of current enrollment in another therapeutic clinical study in the patient profile."
        },
        {
          "id": 7,
          "type": "exclusion",
          "criterion": "Any psychiatric or cognitive disorder that would limit the understanding or rendering of informed consent and/or compromise compliance with the requirements of this study; or known drug abuse/alcohol abuse;",
          "match_result": "negative",
          "comment": "The patient profile indicates that there are no psychiatric or cognitive disorders limiting understanding or rendering of informed consent, nor any known drug abuse/alcohol abuse. Therefore, this criterion is not met by the patient."
        },
        {
          "id": 8,
          "type": "exclusion",
          "criterion": "History of, or currently suspected, diffuse non-infectious pneumonitis or interstitial lung disease including:",
          "match_result": "neutral",
          "comment": "The patient profile provided does not have clear evidence regarding the history of diffuse non-infectious pneumonitis or interstitial lung disease. Further information or clarification is needed in the patient profile to determine if the patient meets this criterion."
        },
        {
          "id": 9,
          "type": "exclusion",
          "criterion": "Clinically important abnormalities in cardiac rhythm, conduction or morphology of resting ECG (e.g. complete left bundle branch block, second degree heart block, third degree heart block) OR:",
          "match_result": "neutral",
          "comment": "The patient profile does not provide information on clinically important abnormalities in cardiac rhythm, conduction, or morphology of resting ECG. Further details regarding the patient's ECG results are needed to determine if this criterion is met."
        },
        {
          "id": 10,
          "type": "exclusion",
          "criterion": "Severely impaired (defined as Child-Pugh Class C) hepatic dysfunction;",
          "match_result": "negative",
          "comment": "The patient profile does not meet the criterion of Severely impaired (defined as Child-Pugh Class C) hepatic dysfunction. The patient's liver function tests (ALT, AST, and Bilirubin) are within normal limits, indicating no severe hepatic dysfunction as per the provided clinical trial criterion."
        },
        {
          "id": 11,
          "type": "exclusion",
          "criterion": "Prior malignancy: Subjects will not be eligible if they have history of, or evidence of active disease of another concurrent malignancy within the previous five years. Exception would be effectively treated past history of non-melanoma skin cancer or in-situ cervical cancer with no evidence of active disease;",
          "match_result": "negative",
          "comment": "The patient has a history of non-small cell lung cancer, which is a malignancy. Even though the patient's lung cancer is not a concurrent malignancy, the presence of active lung cancer within the previous five years does not meet the criteria of not having a history of another concurrent malignancy within the previous five years."
        },
        {
          "id": 12,
          "type": "exclusion",
          "criterion": "Other severe acute or chronic medical condition that may increase the risk associated with study participation or study drug administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study;",
          "match_result": "negative",
          "comment": "The patient profile mentions no severe acute or chronic medical conditions that may increase the risk associated with study participation or study drug administration or interfere with the interpretation of study results. Therefore, the patient does not meet the criterion for exclusion based on this specific medical condition."
        },
        {
          "id": 13,
          "type": "exclusion",
          "criterion": "Use of CYP2D6 substrates where minimal increases in concentration of the CYP2D6 substrate may lead to serious or life-threatening toxicities, including but not limited to procainamide, pimozide, and thioridazine from screening to randomization.",
          "match_result": "neutral",
          "comment": "The patient profile indicates that they are not using any CYP2D6 substrates, which aligns with the criterion. However, more information is needed to definitively determine if the patient meets the criterion, specifically regarding the use of CYP2D6 substrates from screening to randomization."
        },
        {
          "id": 0,
          "type": "inclusion",
          "criterion": "Provision of a voluntarily given, personally signed and dated, written informed consent document;",
          "match_result": "positive",
          "comment": "The patient has the capability to provide informed consent as they do not have any conditions mentioned in the criterion that would prevent them from doing so. The patient's gene mutation, treatment history, biomarkers, and other health status do not conflict with the requirement of providing written informed consent."
        },
        {
          "id": 1,
          "type": "inclusion",
          "criterion": "Male or female adult as defined by local regulation;"
        },
        {
          "id": 2,
          "type": "inclusion",
          "criterion": "The presence of an EGFR activating mutation (exon 19 deletion or the L858R mutation in exon 21) in tumor specimen determined by the local laboratory;",
          "match_result": "positive",
          "comment": "The patient profile indicates the presence of an EGFR activating mutation (exon 19 deletion), which matches the criterion of requiring an EGFR activating mutation (exon 19 deletion or the L858R mutation in exon 21). Therefore, the patient meets this criterion."
        },
        {
          "id": 3,
          "type": "inclusion",
          "criterion": "Evidence of newly diagnosed stage IIIB/IIIC/IV (based on Union for International Cancer Control (UICC) staging system version 8) or recurrent (minimum of 12 months disease free interval between completion of systemic therapy and recurrence of NSCLC required) NSCLC of adenocarcinoma histo- and/or cytopathology or its pathologically accepted variants using tumor specimen (assessed according to accepted standards by a local laboratory). For this purpose the World Health Organization/International Association of Study of Lung Cancer Histologic Classification of Lung Cancer Criteria will be used and the diagnosis of NSCLC NOS (not otherwise specified), squamous or mixed adeno-squamous lung carcinomas will not be allowed;",
          "match_result": "neutral",
          "comment": "The patient profile does not provide clear evidence of newly diagnosed stage IIIB/IIIC/IV or recurrent NSCLC. More information is needed to determine if the patient meets this criterion, such as a specific statement on the cancer stage or recurrence status."
        },
        {
          "id": 4,
          "type": "inclusion",
          "criterion": "Have an ECOG PS of 0 or 1;",
          "match_result": "positive",
          "comment": "The patient has an ECOG PS of 0, which meets the criterion of having an ECOG PS of 0 or 1 as stated in the clinical trial criteria."
        },
        {
          "id": 5,
          "type": "inclusion",
          "criterion": "No prior treatment with systemic therapy for locally advanced or metastatic NSCLC. Completed neoadjuvant/adjuvant chemotherapy/immunotherapy and/or combined modality chemotherapy/radiation therapy permitted only in cases in which there is a minimum of 12 months disease free interval between completion of systemic therapy and recurrence of NSCLC. Prior treatment with a EGFR-TKI or other TKIs is not allowed;",
          "match_result": "negative",
          "comment": "The patient has a documented history of an EGFR activating mutation (exon 19 deletion) and the criterion specifies that prior treatment with an EGFR-TKI is not allowed. Since the patient has this specific gene mutation and has not received systemic therapy for advanced NSCLC, they do not meet the criterion as outlined."
        },
        {
          "id": 6,
          "type": "inclusion",
          "criterion": "Radiologically measurable disease by RECIST v1.1 criteria:",
          "match_result": "positive",
          "comment": "The patient profile meets the criterion as it has radiologically measurable disease in the lung, which is a requirement for the clinical trial. Therefore, the patient satisfies the inclusion criteria for the trial."
        },
        {
          "id": 7,
          "type": "inclusion",
          "criterion": "At least one target lesion that has not previously been radiated, and is measurable according to RECIST v1.1;",
          "match_result": "positive",
          "comment": "The patient has at least one unirradiated target lesion as per RECIST v1.1 criteria. The patient has Non-Small Cell Lung Cancer, Adenocarcinoma with disease occurring in the lung, which aligns with the criterion of having a target lesion that has not previously been radiated. Therefore, the patient profile meets the criterion."
        },
        {
          "id": 8,
          "type": "inclusion",
          "criterion": "Acceptable radiologic procedures for disease assessment include contrast enhanced conventional or spiral computed tomography (CT), or contrast enhanced magnetic resonance imaging (MRI); Non-contrast CT scan is acceptable only for subjects who are both allergic to intravenous contrast and unable to cooperate with MRI, or MRI is not available. The following are not allowed as sole documentation of target lesions: CT component of positron emission tomography (PET)/CT, ultrasound alone, nuclear scans (including bone or PET scans), chest X-ray or bone radiographs, and tumor markers;",
          "match_result": "positive",
          "comment": "The patient has non-small cell lung cancer, adenocarcinoma, with the disease occurring in the lung, which aligns with the criterion for acceptable radiologic procedures for disease assessment. The patient is eligible for the clinical trial based on the radiologic procedures outlined in the criterion."
        },
        {
          "id": 9,
          "type": "inclusion",
          "criterion": "Adequate organ function, including:"
        },
        {
          "id": 10,
          "type": "inclusion",
          "criterion": "Estimated creatinine clearance ≥30 mL/min (as determined by Cockcroft-Gault formula or the study site's standard formula);",
          "match_result": "positive",
          "comment": "The patient has a creatinine clearance of 35 mL/min, which is ≥30 mL/min as required by the clinical trial criterion. The criterion is met based on the patient's profile."
        },
        {
          "id": 11,
          "type": "inclusion",
          "criterion": "Absolute neutrophil count (ANC) ≥1500 cells/mm3;",
          "match_result": "positive",
          "comment": "The patient's Absolute neutrophil count (ANC) is 1600 cells/mm3, which meets the criterion of ANC ≥1500 cells/mm3. Therefore, the patient meets this specific criterion for the clinical trial."
        },
        {
          "id": 12,
          "type": "inclusion",
          "criterion": "Platelets ≥100,000 cells/mm3;",
          "match_result": "positive",
          "comment": "The patient's platelet count is 110,000 cells/mm, which is greater than the required 100,000 cells/mm3 mentioned in the criterion. Therefore, the patient meets the Platelets criterion for the clinical trial."
        },
        {
          "id": 13,
          "type": "inclusion",
          "criterion": "Hemoglobin ≥10.0 g/dL;",
          "match_result": "positive",
          "comment": "Patient's hemoglobin level is 11.0 g/dL, which is greater than the required ≥10.0 g/dL mentioned in the criterion. Therefore, the patient meets the criterion for Hemoglobin ≥10.0 g/dL."
        },
        {
          "id": 14,
          "type": "inclusion",
          "criterion": "Bilirubin ≤1.5 x ULN;",
          "match_result": "positive",
          "comment": "The patient's Total Bilirubin level of 1.2 x ULN meets the criterion of Bilirubin ≤1.5 x ULN as specified in the clinical trial criteria."
        },
        {
          "id": 15,
          "type": "inclusion",
          "criterion": "AST (also known as SGOT) and ALT (also known as SGPT) ≤2.5 x ULN (≤5.0 x ULN if hepatic metastases).",
          "match_result": "positive",
          "comment": "The patient's AST (SGOT) and ALT (SGPT) levels are within normal limits, meeting the criterion of AST and ALT ≤2.5 x ULN. Therefore, the patient meets this specific criterion for the clinical trial."
        },
        {
          "id": 16,
          "type": "inclusion",
          "criterion": "Female subjects must be postmenopausal (defined as 12 months of amenorrhea following last menses), or they or their partners must be surgically sterile, or must agree to use effective contraception while receiving study treatment and for at least 3 months thereafter. The definition of effective contraception will be based on the judgment of the investigator using following criteria:",
          "match_result": "neutral",
          "comment": "The patient profile does not provide explicit information about the menopausal status or contraception use of the female patient. Further details are required to determine if the patient meets the inclusion criterion regarding postmenopausal status, surgical sterilization, or effective contraception use."
        },
        {
          "id": 17,
          "type": "inclusion",
          "criterion": "All female subjects with reproductive potential must have a negative pregnancy test (serum or urine) prior to starting study treatment;",
          "match_result": "neutral",
          "comment": "The patient profile does not provide information regarding the pregnancy test status for female subjects with reproductive potential. Additional information is needed to determine if this criterion is met."
        },
        {
          "id": 18,
          "type": "inclusion",
          "criterion": "Male subjects or their female partners must be surgically sterile or must agree to use effective contraception while receiving study treatment and for at least 3 months thereafter. The definition of effective contraception will be based on the judgment of the investigator. Or female partners must be postmenopausal (defined as 12 months of amenorrhea following last menses);",
          "match_result": "neutral",
          "comment": "The patient profile does not provide sufficient information regarding the patient's or their female partner's sterility or contraceptive methods. Additional details are needed to determine if this criterion is met."
        },
        {
          "id": 19,
          "type": "inclusion",
          "criterion": "Willing and able to comply with study scheduled visits, treatment plans, laboratory tests, and other study procedures.",
          "match_result": "positive",
          "comment": "The patient is willing and able to comply with study scheduled visits, treatment plans, laboratory tests, and other study procedures as there is no evidence in the patient profile indicating otherwise. The patient meets this criterion."
        }
      ]
    },
    {
      "trial_id": "NCT05261399",
      "gpt_result_score": 4,
      "embedding_score": 3,
      "criteria": [
        {
          "id": 0,
          "type": "exclusion",
          "criterion": "Predominant squamous NSCLC, and small cell lung cancer. Prior or current treatment with a third-generation EGFR-TKI other than Osimertinib. Prior or current treatment with savolitinib or another MET inhibitors. Spinal cord compression or brain metastases, unless asymptomatic and are stable. History or active leptomeningeal carcinomatosis. Unresolved toxicities from any prior therapy greater than CTCAE Grade 1 with the exception of alopecia, haemoglobin ≥ 9.0 g/dL, and Grade 2 prior platinum-therapy related neuropathy. Active/unstable cardiac diseases currently or within the last 6 months, clinically significant ECG abnormalities, and/or factors/medications that may affect QTc intervals. History of liver cirrhosis of any origin and clinical stage; or history of other serious liver disease or chronic disease with relevant liver involvement. Known serious active infection including, but not limited to, tuberculosis, or HIV, HBV or HCV or gastrointestinal disease. Receipt of live attenuated vaccine (including against COVID-19) within 30 days prior to the first dose of study intervention. Past medical history of ILD, drug-induced ILD, radiation pneumonitis, which required steroid treatment, or any evidence of clinically active ILD. Participants currently receiving medications or herbal supplements known to be strong inducers of cytochrome P450 (CYP)3A4 or strong inhibitors of CYP1A2.",
          "match_result": "neutral",
          "comment": "The patient profile is missing specific information required to determine if they meet the clinical trial criterion. More details are needed on factors such as prior treatments with third-generation EGFR-TKI other than Osimertinib, MET inhibitors, cardiac diseases, liver cirrhosis, serious active infections, ILD history, and medications affecting CYP3A4 and CYP1A2 inducers/inhibitors."
        },
        {
          "id": 0,
          "type": "inclusion",
          "criterion": "Provision of signed and dated written ICF prior to any mandatory and non-mandatory study-specific procedures, sampling and analyses. Participant must be ≥18 years (≥ 20 years of age in Japan) at the time of signing the informed consent. All genders are permitted."
        },
        {
          "id": 1,
          "type": "inclusion",
          "criterion": "Histologically or cytologically confirmed locally advanced or metastatic NSCLC which is not amenable to curative therapy. Must have at least one documented sensitising EGFR mutation: exon19 deletion, L858R mutation, and/or T790M. Documented radiologic progression on first- or second-line treatment with osimertinib as the most recent anti-cancer therapy. Mandatory provision of FFPE tumour tissue. MET overexpression and/or amplification in tumour specimen collected following progression on prior osimertinib treatment. Measurable disease as defined by RECIST 1.1. Adequate haematological, liver, renal and cardiac functions, and coagulation parameters. ECOG performance status of 0 or 1.",
          "match_result": "neutral",
          "comment": "The patient profile provides some information that matches the criterion such as the presence of EGFR activating mutation (exon 19 deletion), ECOG score of 0, and no history of small cell or carcinoid lung cancer. However, more information is needed to confirm if the patient meets all the criteria such as documented radiologic progression on first- or second-line treatment with osimertinib, mandatory provision of FFPE tumour tissue, MET overexpression and/or amplification, and specific values for adequate haematological, liver, renal, and cardiac functions."
        },
        {
          "id": 2,
          "type": "inclusion",
          "criterion": "Participant must be ≥18 years (≥ 20 years of age in Japan) at the time of signing the informed consent. All genders are permitted."
        },
        {
          "id": 3,
          "type": "inclusion",
          "criterion": "Documented radiologic progression on first- or second-line treatment with osimertinib as the most recent anti-cancer therapy.",
          "match_result": "neutral",
          "comment": "Based on the provided patient profile, it is unclear whether the patient meets the criterion as there is no information regarding documented radiologic progression on first- or second-line treatment with osimertinib as the most recent anti-cancer therapy. Further information is needed to determine if the patient meets this criterion."
        },
        {
          "id": 4,
          "type": "inclusion",
          "criterion": "Mandatory provision of FFPE tumour tissue.",
          "match_result": "positive",
          "comment": "The patient meets the criterion as they have Non-Small Cell Lung Cancer, Adenocarcinoma with mandatory provision of FFPE tumour tissue available for the clinical trial."
        },
        {
          "id": 5,
          "type": "inclusion",
          "criterion": "MET overexpression and/or amplification in tumour specimen collected following progression on prior osimertinib treatment.",
          "match_result": "neutral",
          "comment": "The patient profile provides information on the EGFR activating mutation and the lack of prior systemic therapy for advanced NSCLC. However, specific details on MET overexpression and/or amplification following progression on prior osimertinib treatment are not provided. More information is needed to determine if the patient meets this criterion."
        },
        {
          "id": 6,
          "type": "inclusion",
          "criterion": "Measurable disease as defined by RECIST 1.1.",
          "match_result": "positive",
          "comment": "The patient has Non-Small Cell Lung Cancer, Adenocarcinoma with disease occurred in lung, which fulfills the criterion of having measurable disease as defined by RECIST 1.1."
        },
        {
          "id": 7,
          "type": "inclusion",
          "criterion": "Adequate haematological, liver, renal and cardiac functions, and coagulation parameters.",
          "match_result": "positive",
          "comment": "The patient meets the criterion of having adequate haematological, liver, renal, and cardiac functions, and coagulation parameters. The patient's biomarkers indicate Platelets: 110,000 cells/mm, Creatinine: 35 mL/min, ALT (SGPT): Within normal limits, AST (SGOT): Within normal limits, Bilirubin, Total: 1.2 x ULN, ANC: 1600 cells/mm, Hemoglobin: 11.0 g/dL, and Bilirubin: 1.2 x ULN, which all fall within the acceptable range for this criterion."
        },
        {
          "id": 8,
          "type": "inclusion",
          "criterion": "ECOG performance status of 0 or 1.",
          "match_result": "positive",
          "comment": "The patient's ECOG performance status is 0, which meets the criterion of ECOG performance status of 0 or 1. Therefore, the patient profile matches the criterion."
        }
      ]
    },
    {
      "trial_id": "NCT04989322",
      "gpt_result_score": 3,
      "embedding_score": 4,
      "criteria": [
        {
          "id": 0,
          "type": "exclusion",
          "criterion": "Prior exposure to immunotherapy or chemotherapy",
          "match_result": "negative",
          "comment": "The patient profile mentions that no systemic therapy has been received for advanced NSCLC, which indicates that the patient has not been exposed to immunotherapy or chemotherapy. Therefore, the criterion of 'Prior exposure to immunotherapy or chemotherapy' is present in the patient profile but is not met, resulting in a negative match result."
        },
        {
          "id": 1,
          "type": "exclusion",
          "criterion": "Active untreated brain metastasis and/or carcinomatous meningitis",
          "match_result": "negative",
          "comment": "The patient profile does not include any evidence of active untreated brain metastasis or carcinomatous meningitis. Although the patient has Non-Small Cell Lung Cancer, Adenocarcinoma, the disease occurred in the lung and there is no indication of brain metastasis or carcinomatous meningitis in the provided information."
        },
        {
          "id": 2,
          "type": "exclusion",
          "criterion": "Active, known or suspected autoimmune disease",
          "match_result": "negative",
          "comment": "The patient profile does not have active, known or suspected autoimmune disease, which meets the criterion mentioned in the clinical trial requirement."
        },
        {
          "id": 3,
          "type": "exclusion",
          "criterion": "History of (noninfectious) pneumonitis that required systemic steroids or current pneumonitis/interstitial lung disease",
          "match_result": "negative",
          "comment": "The patient has a history of noninfectious pneumonitis that required systemic steroids, which is an exclusion criterion for the clinical trial. Therefore, the patient does not meet this criterion."
        },
        {
          "id": 4,
          "type": "exclusion",
          "criterion": "Condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalent) or other immunosuppressive medications",
          "match_result": "negative",
          "comment": "The patient profile mentions that no systemic therapy has been received for advanced NSCLC, which indicates that the patient has not been treated with corticosteroids or other immunosuppressive medications. Therefore, the patient does not meet the criterion requiring systemic treatment with corticosteroids or other immunosuppressive medications."
        },
        {
          "id": 5,
          "type": "exclusion",
          "criterion": "Baseline proteinuria ≥ 1 g/24 hrs"
        },
        {
          "id": 6,
          "type": "exclusion",
          "criterion": "Electrolyte abnormalities that have not been corrected",
          "match_result": "negative",
          "comment": "The patient profile indicates that the Platelets count is 110,000 cells/mm, which is below the normal range. This matches the criterion of 'Electrolyte abnormalities that have not been corrected'. As the Platelets count is considered an electrolyte abnormality and it has not been corrected, the patient does not meet this criterion."
        },
        {
          "id": 7,
          "type": "exclusion",
          "criterion": "Significant cardiovascular impairment",
          "match_result": "neutral",
          "comment": "The patient profile does not provide explicit information regarding significant cardiovascular impairment. Further details or specific tests related to cardiovascular function are needed to determine if the patient meets the criterion."
        },
        {
          "id": 8,
          "type": "exclusion",
          "criterion": "Gastrointestinal pathology that might affect the absorption of lenvatinib",
          "match_result": "neutral",
          "comment": "More information is needed from the patient profile to determine if the gastrointestinal pathology might affect the absorption of lenvatinib. The current profile does not provide specific details related to gastrointestinal pathology that could influence drug absorption."
        },
        {
          "id": 9,
          "type": "exclusion",
          "criterion": "Preexisting grade ≥ 3 gastrointestinal or non gastrointestinal fistula",
          "match_result": "neutral",
          "comment": "The patient profile does not provide specific information regarding preexisting grade ≥ 3 gastrointestinal or non-gastrointestinal fistula. Further details or medical history are needed to determine if the patient meets this exclusion criterion."
        },
        {
          "id": 10,
          "type": "exclusion",
          "criterion": "Bleeding or thrombotic disorders or subjects at risk for severe hemorrhage",
          "match_result": "negative",
          "comment": "The patient profile mentions no bleeding or thrombotic disorders, and there is no mention of being at risk for severe hemorrhage. Therefore, the patient does not meet the criterion of having bleeding or thrombotic disorders or being at risk for severe hemorrhage."
        },
        {
          "id": 11,
          "type": "exclusion",
          "criterion": "Radiographic evidence of intratumoral caviations, encasement, or invasion of a major blood vessel",
          "match_result": "negative",
          "comment": "The patient profile mentions the disease occurred in the lung which aligns with the criterion mentioning intratumoral caviations, encasement, or invasion of a major blood vessel. However, there is no specific radiographic evidence provided in the patient profile to confirm this criterion. Therefore, the patient does not meet this exclusion criterion."
        },
        {
          "id": 12,
          "type": "exclusion",
          "criterion": "Known history of tuberculosis",
          "match_result": "negative",
          "comment": "The patient profile does not have a known history of tuberculosis, so it meets the exclusion criterion for the clinical trial."
        },
        {
          "id": 13,
          "type": "exclusion",
          "criterion": "Active, acute, or chronic clinically significant infections requiring therapy, including hepatitis B, hepatitis C, and HIV",
          "match_result": "neutral",
          "comment": "The patient profile does not provide explicit information about current active, acute, or chronic clinically significant infections requiring therapy including hepatitis B, hepatitis C, and HIV. Further information is needed to determine if the patient meets this exclusion criterion."
        },
        {
          "id": 14,
          "type": "exclusion",
          "criterion": "ECG with long QTc interval ≥ 470 ms",
          "match_result": "neutral",
          "comment": "The patient profile does not provide information regarding ECG findings, specifically the QTc interval, which is required to determine if the criterion is met or not. Further investigation or testing is needed to confirm if the patient meets the ECG criterion."
        },
        {
          "id": 0,
          "type": "inclusion",
          "criterion": "Histologically proven NSCLC",
          "match_result": "positive",
          "comment": "The patient profile confirms the criterion of 'Histologically proven NSCLC' as the patient has Non-Small Cell Lung Cancer, specifically Adenocarcinoma, which is a histological subtype of NSCLC."
        },
        {
          "id": 1,
          "type": "inclusion",
          "criterion": "Unresectable or metastatic NSCLC, including squamous cell carcinoma, harboring sensitizing EGFR, ALK, or ROS1 genetic aberrations who have received standard of care targeted therapy and have progressed on treatment. Patients with known T790M mutation should have received osimertinib and failed.",
          "match_result": "neutral",
          "comment": "The patient profile indicates the presence of Non-Small Cell Lung Cancer with an EGFR activating mutation, which aligns with the genetic aberrations mentioned in the criteria. However, the patient has not received standard of care targeted therapy for advanced NSCLC, which is a key requirement of the trial criteria. More information is needed about the patient's treatment history to determine if they meet the criterion."
        },
        {
          "id": 2,
          "type": "inclusion",
          "criterion": "Measurable disease per RECIST 1.1",
          "match_result": "positive",
          "comment": "The patient has Non-Small Cell Lung Cancer with measurable disease in the lung, which meets the criterion of having measurable disease per RECIST 1.1."
        },
        {
          "id": 3,
          "type": "inclusion",
          "criterion": "ECOG performance status ≤ 1",
          "match_result": "positive",
          "comment": "The patient's ECOG performance status is 0 which is less than or equal to 1, meeting the criterion of ECOG performance status ≤ 1 for inclusion in the clinical trial."
        },
        {
          "id": 4,
          "type": "inclusion",
          "criterion": "Adequate organ function"
        },
        {
          "id": 5,
          "type": "inclusion",
          "criterion": "Adequately controlled blood pressure",
          "match_result": "neutral",
          "comment": "More information is needed regarding the patient's blood pressure status to determine if it is adequately controlled as per the clinical trial criterion."
        }
      ]
    },
    {
      "trial_id": "NCT05526755",
      "gpt_result_score": 2.7,
      "embedding_score": 2,
      "criteria": [
        {
          "id": 0,
          "type": "exclusion",
          "criterion": "Major surgery (including primary tumour surgery, excluding placement of vascular access) within 4 weeks prior to the first dose of study drug.",
          "match_result": "neutral",
          "comment": "The patient profile does not provide clear information regarding whether the patient underwent major surgery within 4 weeks prior to the first dose of study drug. More specific details are needed to determine if this criterion is met."
        },
        {
          "id": 1,
          "type": "exclusion",
          "criterion": "Participants currently receiving medications or herbal supplements known to be potent inducers of CYP3A4 (at least 3 weeks prior to first dose).",
          "match_result": "neutral",
          "comment": "The patient profile does not provide specific information regarding the current use of medications or herbal supplements known to be potent inducers of CYP3A4. Further clarification is needed to determine if the patient meets the exclusion criterion."
        },
        {
          "id": 2,
          "type": "exclusion",
          "criterion": "Participants who have had only segmentectomies or wedge resections.",
          "match_result": "negative",
          "comment": "The patient has had no segmentectomies or wedge resections, which aligns with the criterion of not having had only segmentectomies or wedge resections. Therefore, the patient profile does not meet the exclusion criterion."
        },
        {
          "id": 3,
          "type": "exclusion",
          "criterion": "History of other malignancies, except: adequately treated non-melanoma skin cancer, curatively treated in situ cancer, or other solid tumours curatively treated with no evidence of disease for > 5 years following the end of study intervention.",
          "match_result": "neutral",
          "comment": "The patient profile does not provide clear information regarding the history of other malignancies. Further details are needed to determine if the patient meets the criterion of no history of other malignancies, except for specific exceptions listed in the clinical trial criteria."
        },
        {
          "id": 4,
          "type": "exclusion",
          "criterion": "Pre-operative or post-operative or planned radiation therapy for the current lung cancer.",
          "match_result": "negative",
          "comment": "The patient profile indicates that the patient has not received pre-operative or post-operative or planned radiation therapy for the current lung cancer. Therefore, the criterion is met and the result is negative, as the patient does not meet the exclusion criteria for the clinical trial."
        },
        {
          "id": 5,
          "type": "exclusion",
          "criterion": "Pre-operative (neo-adjuvant) platinum-based or other chemotherapy.",
          "match_result": "neutral",
          "comment": "The patient profile does not provide clear information about whether the patient has received pre-operative platinum-based or other chemotherapy. More details are needed to determine if the patient meets this criterion."
        },
        {
          "id": 6,
          "type": "exclusion",
          "criterion": "Any prior anticancer or immunological therapy, including investigational therapy, for treatment of NSCLC other than standard platinum-based doublet post-operative adjuvant chemotherapy.",
          "match_result": "positive",
          "comment": "The patient has not received any prior anticancer or immunological therapy for treatment of NSCLC, meeting the criterion stated in the clinical trial. The patient has also not received any systemic therapy for advanced NSCLC, which aligns with the criterion of excluding prior treatment for NSCLC."
        },
        {
          "id": 7,
          "type": "exclusion",
          "criterion": "Prior treatment with neoadjuvant or adjuvant EGFR tyrosine kinase inhibitor (TKI).",
          "match_result": "negative",
          "comment": "The patient has an EGFR activating mutation and has not received neoadjuvant or adjuvant EGFR tyrosine kinase inhibitor (TKI) treatment, which meets the criterion. Therefore, the patient does not match the exclusion criterion stated."
        },
        {
          "id": 8,
          "type": "exclusion",
          "criterion": "Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product, or previous significant bowel resection that would preclude adequate absorption of osimertinib.",
          "match_result": "negative",
          "comment": "The patient has not been reported to have refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product, or previous significant bowel resection. Therefore, the patient does not meet the exclusion criterion mentioned in the clinical trial."
        },
        {
          "id": 9,
          "type": "exclusion",
          "criterion": "Any of the following cardiac criteria: Mean resting corrected QT (QTc) interval > 470 msec, obtained from 3 electrocardiograms (ECGs). Any clinically important abnormalities in rhythm, conduction, or morphology of resting ECG. Any factors that increase the risk of QTc prolongation or risk of arrhythmic events. Heart failure, congenital long QT interval (QT) syndrome, family history of long QT syndrome or unexplained sudden death under 40 years of age in first-degree relatives or any concomitant medication known to prolong the QT interval and cause Torsades de Pointes (TdP).",
          "match_result": "neutral",
          "comment": "More information is needed from the patient profile to determine if the patient meets the cardiac criteria specified in the clinical trial. The patient profile does not provide specific details regarding the Mean resting corrected QT (QTc) interval, ECG abnormalities, history of heart failure, congenital long QT syndrome, family history of long QT syndrome or sudden death under 40 years of age in first-degree relatives, or concomitant medications known to prolong the QT interval."
        },
        {
          "id": 10,
          "type": "exclusion",
          "criterion": "Past medical history of interstitial lung disease (ILD), drug-induced ILD, radiation pneumonitis that required steroid treatment, or any evidence of clinically active ILD.",
          "match_result": "negative",
          "comment": "The patient has a history of Non-Small Cell Lung Cancer, but there is no evidence of past medical history of interstitial lung disease (ILD), drug-induced ILD, radiation pneumonitis that required steroid treatment, or any evidence of clinically active ILD. Therefore, the patient does not meet the criterion for exclusion based on ILD history."
        },
        {
          "id": 11,
          "type": "exclusion",
          "criterion": "Inadequate bone marrow reserve or organ function.",
          "match_result": "negative",
          "comment": "The patient's biomarkers such as Platelets (110,000 cells/mm) and Creatinine (35 mL/min) indicate inadequate organ function, which does not meet the criteria for adequate bone marrow reserve or organ function."
        },
        {
          "id": 12,
          "type": "exclusion",
          "criterion": "Women who are breastfeeding."
        },
        {
          "id": 13,
          "type": "exclusion",
          "criterion": "Heart failure, congenital long QT interval  QT  syndrome, family history of long QT syndrome or unexplained sudden death under 40 years of age in first-degree relatives or any concomitant medication known to prolong the QT interval and cause Torsades de Pointes  TdP .",
          "match_result": "neutral",
          "comment": "The patient profile does not provide clear information related to heart failure, congenital long QT interval syndrome, family history of long QT syndrome, sudden death under 40 years of age in first-degree relatives, or concomitant medication known to prolong the QT interval and cause Torsades de Pointes. Additional information is needed to determine if the patient meets the criterion."
        },
        {
          "id": 14,
          "type": "exclusion",
          "criterion": "Past medical history of interstitial lung disease  ILD , drug-induced ILD, radiation pneumonitis that required steroid treatment, or any evidence of clinically active ILD.",
          "match_result": "negative",
          "comment": "The patient has a past medical history of lung cancer (Non-Small Cell Lung Cancer, Adenocarcinoma) but there is no evidence or history of interstitial lung disease (ILD), drug-induced ILD, or radiation pneumonitis that required steroid treatment. Therefore, the patient does not meet the criterion of having a past medical history of ILD as stated in the clinical trial criteria."
        },
        {
          "id": 15,
          "type": "exclusion",
          "criterion": "Inadequate bone marrow reserve or organ function.",
          "match_result": "negative",
          "comment": "The patient profile provides information on organ function and bone marrow reserve through biomarkers such as Platelets, Creatinine, ALT, AST, Bilirubin, ANC, Hemoglobin. The results indicate low platelet count (110,000 cells/mm), low creatinine clearance (35 mL/min), and a low ANC count (1600 cells/mm), which suggest inadequate bone marrow reserve and potentially impaired organ function. Therefore, the patient does not meet the criterion of having adequate bone marrow reserve or organ function."
        },
        {
          "id": 16,
          "type": "exclusion",
          "criterion": "Women who are breastfeeding."
        },
        {
          "id": 0,
          "type": "inclusion",
          "criterion": "Male or female aged at least 18 years."
        },
        {
          "id": 1,
          "type": "inclusion",
          "criterion": "Histologically confirmed diagnosis of primary NSCLC on predominantly non-squamous histology.",
          "match_result": "positive",
          "comment": "The patient has Non-Small Cell Lung Cancer with Adenocarcinoma histology, which meets the criterion of having predominantly non-squamous histology. Therefore, the patient profile confirms the histologically confirmed diagnosis of primary NSCLC on predominantly non-squamous histology."
        },
        {
          "id": 2,
          "type": "inclusion",
          "criterion": "Magnetic Resonance Imaging (MRI) or contrast computed tomography (CT) scan of the brain.",
          "match_result": "neutral",
          "comment": "The patient profile provides detailed information about the disease, gene mutation, ECOG score, treatment history, biomarkers, and other health status. However, there is no specific mention of whether the patient has undergone Magnetic Resonance Imaging (MRI) or contrast computed tomography (CT) scan of the brain. More information is needed to determine if this criterion is met."
        },
        {
          "id": 3,
          "type": "inclusion",
          "criterion": "Participants must be classified post-operatively as Stage II, IIIA, or IIIB on the basis of surgical pathologic criteria.",
          "match_result": "neutral",
          "comment": "More information is needed from the Patient profile to determine if the patient meets the criterion. The patient profile provides information about the type of lung cancer (Non-Small Cell Lung Cancer, Adenocarcinoma) and gene mutation (EGFR activating mutation), but specific post-operative staging information is required to determine if the patient meets the Stage II, IIIA, or IIIB classification based on surgical pathologic criteria as stated in the clinical trial criterion."
        },
        {
          "id": 4,
          "type": "inclusion",
          "criterion": "Confirmation by the local laboratory that the tumour harbours one of the two common EGFR mutations (Ex19del, L858R), either alone or in combination with other EGFR mutations including de novo EGFR mutation resulting in substitution of threonine with methionine at amino acid position 790 in exon 20 of EGFR (T790M) or uncommon EGFR mutations G719X, S768I, and L861Q, either alone, in combination with each other, or in combination with other uncommon EGFR mutations (excluding all exon 20 insertions) (Uncommon EGFRm Cohort).",
          "match_result": "positive",
          "comment": "The patient has Non-Small Cell Lung Cancer with Adenocarcinoma, and the gene mutation is EGFR activating mutation (exon 19 deletion) which matches the criterion of having one of the common EGFR mutations (Ex19del). The patient also does not have EGFR exon 20 T790M mutation. Therefore, the patient meets the criteria as they have one of the common EGFR mutations specified in the trial criterion."
        },
        {
          "id": 5,
          "type": "inclusion",
          "criterion": "Complete surgical resection of the primary NSCLC is mandatory. All gross disease must have been removed at the end of surgery. All surgical margins of resection must be negative for tumour.",
          "match_result": "neutral",
          "comment": "The patient profile mentions the presence of Non-Small Cell Lung Cancer, Adenocarcinoma in the lung, and the absence of Small Cell or Carcinoid lung cancer. However, more information is needed to confirm if complete surgical resection of the primary NSCLC has been performed and if all surgical margins are negative for tumor, as required by the clinical trial criterion."
        },
        {
          "id": 6,
          "type": "inclusion",
          "criterion": "Complete recovery from surgery and standard post-operative therapy (if applicable) at start of study intervention.",
          "match_result": "neutral",
          "comment": "The patient profile contains some information related to recovery from surgery, such as no systemic therapy received for advanced NSCLC, RECIST v1.1 assessment with unirradiated target lesion, ECOG score of 0, and normal liver function tests. However, there is no explicit mention of complete recovery from surgery and standard post-operative therapy at the start of study intervention. More information is needed to determine if the patient meets this criterion."
        },
        {
          "id": 7,
          "type": "inclusion",
          "criterion": "World Health Organisation Performance Status of 0 to 1.",
          "match_result": "positive",
          "comment": "The patient meets the criterion of World Health Organisation Performance Status of 0 to 1 as their ECOG score is 0, indicating a good level of performance status."
        },
        {
          "id": 8,
          "type": "inclusion",
          "criterion": "Female participants must be using highly effective contraceptive measures, and must have a negative pregnancy test prior to start of dosing if of childbearing potential.",
          "match_result": "neutral",
          "comment": "The patient profile provided does not contain information regarding the use of highly effective contraceptive measures or a negative pregnancy test. More information is needed to determine if the patient meets this specific criterion."
        },
        {
          "id": 9,
          "type": "inclusion",
          "criterion": "Male participants must use effective barrier contraception.",
          "match_result": "neutral",
          "comment": "The patient profile does not provide clear information about whether the male participant is using effective barrier contraception. More information is needed to determine if this criterion is met."
        }
      ]
    },
    {
      "trial_id": "NCT05133544",
      "gpt_result_score": 0,
      "embedding_score": 1,
      "criteria": [
        {
          "id": 0,
          "type": "exclusion",
          "criterion": "Patients will be excluded if they have history of inflammatory bowel disease, colorectal cancer, previous bowel resection, Peutz-Jeghers syndrome, familial adenomatous polyposis or other polyposis syndromes, bleeding tendency or severe comorbid illnesses for which polypectomy is considered unsafe.",
          "match_result": "negative",
          "comment": "The patient has no history of inflammatory bowel disease, colorectal cancer, previous bowel resection, Peutz-Jeghers syndrome, familial adenomatous polyposis, bleeding tendency, or severe comorbid illnesses. Therefore, they meet the exclusion criterion for the clinical trial."
        },
        {
          "id": 1,
          "type": "exclusion",
          "criterion": "Moreover, after randomization, if the cecum could not be intubated for various reasons or Boston Bowel Preparation Scale (BBPS) score is <2, these patients will be excluded",
          "match_result": "neutral",
          "comment": "The patient profile does not provide information regarding the cecum intubation or the Boston Bowel Preparation Scale (BBPS) score, which are key factors in determining if the patient meets the exclusion criterion. More information is needed to determine if the patient meets this criterion."
        },
        {
          "id": 0,
          "type": "inclusion",
          "criterion": "All adult patients, aged 40 or above, undergoing outpatient colonoscopy in the Queen Mary Hospital, Tung Wah Hospital and Tuen Mun Hospital in Hong Kong will be recruited.",
          "match_result": "neutral",
          "comment": "The patient profile provided does not specify the age of the patient. More information is needed to determine if the patient meets the criterion of being aged 40 or above as required in the clinical trial criteria."
        }
      ]
    }
  ]
}